Boundless Bio, Inc. (BOLD) vs Connect Biopharma Holdings Limited (CNTB)
A side-by-side comparison of Boundless Bio, Inc. and Connect Biopharma Holdings Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BOLD
Boundless Bio, Inc.
$2.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
CNTB
Connect Biopharma Holdings Limited
$0.91HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BOLD vs CNTB
growth of $100 · dividends reinvested · last 3yBOLD -81.8% (-43.3%/yr)CNTB -44.2% (-17.7%/yr)CNTB compounded faster over this window
BOLD CNTB
BOLD vs CNTB: by the numbers
- •BOLD is the larger company ($58M vs $57M market cap).
- •Both run net losses; BOLD's is the smaller (0.00% vs -86687.50% net margin).
Metrics side by side
Valuation
| Metric | BOLD | CNTB |
|---|---|---|
| P/B ratio | 0.88 | 2.12 |
Profitability
| Metric | BOLD | CNTB |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -90740.62% |
| Net margin | 0.00% | -86687.50% |
| ROE | -58.99% | -132.16% |
| ROIC | -43.97% | -136.77% |
Growth (annualized)
| Metric | BOLD | CNTB |
|---|---|---|
| Total return CAGR (5Y) | N/A | -47.22% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.